Boc-β-Ala-Osu

Catalog No. :
ACFYWJ327
CAS No. :
32703-87-0
Molecular Formula :
C12H18N2O6
Molecular Weight :
286.28

IUPAC Name:2,5-dioxopyrrolidin-1-yl 3-((tert-butoxycarbonyl)amino)propanoate

Boc-β-Ala-Osu structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100g95%$126.00Login to see priceIn stockInquiry
500g95%$630.00Login to see priceIn stockInquiry
1000g95%$1259.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBoc-β-Ala-Osu
IUPAC Name2,5-dioxopyrrolidin-1-yl 3-((tert-butoxycarbonyl)amino)propanoate
MDL No.MFCD00038647
Molecular FormulaC12H18N2O6
Molecular Weight286.28
SMILESO=C(OC(C)(C)C)NCCC(ON1C(CCC1=O)=O)=O
InChI KeyTVWATMRQKCTKAU-UHFFFAOYSA-N
SynonymBoc-b-Ala-Osu | 2,5-dioxopyrrolidin-1-yl 3-(tert-butoxycarbonylamino)propanoate | A-Ala-Osu | Boc- | Boc-Beta-Ala-OSu | AKOS016003109 | Tox21_201601 | TVWATMRQKCTKAU-UHFFFAOYSA-N | AI3-28763 | DTXSID90443523 | CS-0148556 | Boc-I(2)-Ala-Osu | Boc-b-Alanine
CAS No.32703-87-0
PubChem CID10684599

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACFYWJ327 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNXWU652 route compound structure diagram
    ACNXWU6523303-84-2 In Stock
  2. Plus
  3. ACPOQL635 route compound structure diagram
    ACPOQL6356066-82-6 In Stock
  4. Then
  5. ACFYWJ327 route product structure diagram
    ACFYWJ32732703-87-0 In Stock
Inquiry

2. ACFYWJ327 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNXWU652 route compound structure diagram
    ACNXWU6523303-84-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFYWJ327 route product structure diagram
    ACFYWJ32732703-87-0 In Stock
Inquiry

Comments (0)